Abcuro Company
Abcuro develops first-in-class immunotherapies to treat autoimmunity and cancer.
Technology:
Cell-based gene therapy
Industry:
Private
Headquarters:
Newton, Massachusetts, United States
Founded Date:
2015-01-01
Employees Number:
1-10
Funding Status:
Early Stage Venture
Investors Number:
9
Total Funding:
59849990
Estimated Revenue:
Less than $1M
Last Funding Date:
2021-01-07
Last Funding Type:
Series A
Register and Claim Ownership